Trubion Pharmaceuticals Provides Announcement Dates for First-Quarter Earnings Conference Call
May 01 2008 - 5:00PM
PR Newswire (US)
SEATTLE, May 1 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals,
Inc. (NASDAQ:TRBN), today announced it plans to issue earnings
results for the first quarter ended March 31, 2008, after the close
of market on May 8, 2008. The company's earnings conference call
will take place May 8, 2008, at 2 p.m. PDT (5 p.m. EDT). Both live
events will be available for viewing on Trubion's website at
http://investors.trubion.com/events.cfm. First-Quarter Earnings
Conference Call: 2 p.m. PDT / 5 p.m. EDT, May 8, 2008 Participants
are invited to call 1(877) 545-1488 or 1 (719) 325-4899. A replay
of the discussion will be available after 5 p.m. PDT / 8 p.m. EDT
by visiting Trubion's website or by calling 1(888) 203-1112 or 1
(719) 457-0820, and entering 7602146. The replay will be available
until midnight, Monday, May 12. About Trubion Trubion is a
biopharmaceutical company that is creating a pipeline of novel
protein therapeutic product candidates to treat autoimmune and
inflammatory diseases and cancer. The company's mission is to
develop a variety of first-in-class and best-in-class product
candidates, customized for optimal safety, efficacy, and
convenience that it believes may offer improved patient
experiences. Trubion's current product candidates are novel
single-chain protein, or SMIP(TM), therapeutics, and are designed
using its custom drug assembly technology. Trubion's product
pipeline includes CD20-directed candidates such as TRU-015 and
SBI-087 for autoimmune and inflammatory diseases, developed under
the company's Wyeth collaboration. Trubion's proprietary product
candidate, TRU-016, is a novel CD37-targeted therapy for the
treatment of B-cell malignancies currently in Phase 1/2 clinical
evaluation. In addition to Trubion's current product candidates,
the company is also developing additional alliance and proprietary
product candidates that build on its product development
experience. More information is available in the investors section
of Trubion's website: investors.trubion.com. Jim DeNike Senior
Director, Corporate Communications Trubion Pharmaceuticals, Inc.
(206) 838-0500 http://www.trubion.com/ TRBN-G DATASOURCE: Trubion
Pharmaceuticals, Inc. CONTACT: Jim DeNike, Senior Director,
Corporate Communications of Trubion Pharmaceuticals, Inc.,
+1-206-838-0500, Web site: http://www.trubion.com/
Copyright
Trubion Pharmaceuticals (MM) (NASDAQ:TRBN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Trubion Pharmaceuticals (MM) (NASDAQ:TRBN)
Historical Stock Chart
From Jul 2023 to Jul 2024